Future Perspectives in Percutaneous Treatment of Tricuspid Regurgitation

Frontiers in Cardiovascular Medicine

Andrea Fisicaro¹  Antonio Mangieri¹  Francesco Gallo¹  Arif Khokhar¹  Antonio Colombo¹  Francesco Giannini¹  Alessandra Laricchia¹  Mei Chau²  Edwin Ho³  Azeem Latib³  Ythan Goldberg³  Matteo Pagnesi⁴  Damiano Regazzoli⁵ 

[1] Cardiovascular Department, GVM Care and Research, Maria Cecilia Hospital, Cotignola, Italy;Department of Cardiac Surgery, Montefiore Medical Center, New York, NY, United States;Department of Cardiology, Montefiore Medical Center, New York, NY, United States;San Raffaele Scientific Institute, Milan, Italy;Unit of Cardiovascular Interventions, Humanitas Research Hospital, Rozzano, Italy;

关键词: transcatheter tricuspid valve intervention;    transcatheter tricuspid valve replacement;    tricuspid valve;    tricuspid regurgitation;    intracardiac echocardiography;    transesophageal echocardiography;   

DOI  :  10.3389/fcvm.2020.581211

来源: DOAJ

【 摘 要 】

Tricuspid regurgitation (TR) has a not negligible prevalence and its severity is correlated with poorer outcomes. However, surgical options are rarely offered to these patients because of their high surgical risk. Given that medical therapy plays a limited role in the management of these patients, there is an increasing clinical need for transcatheter treatment options. Although, transcatheter tricuspid valve interventions (TTVIs) are still at an early stage, emerging data suggests their clinical effectiveness and safety, with preliminary results highlighting the potential benefits of transcatheter treatments over medical therapy. In this review, we highlight the challenges and future directions of current and emerging technologies dedicated to the treatment of TR along with an analysis of the next steps required in future clinical trials and studies dedicated to the treatment of the forgotten valve.

【 授权许可】

Unknown